Answers are grounded in this paper and cite their sources.
Lipid-lowering randomised clinical trials (RCTs) form the foundation of guideline recommendations for secondary atherosclerotic cardiovascular disease (ASCVD) prevention. Many of these trials were conducted decades ago using strict eligibility criteria, which may limit their applicability to the diverse population of contemporary real-world ASCVD patients. Furthermore, common comorbidities and key demographic groups are often underrepresented in lipid-lowering RCTs.1 Here, a study2 investigated the applicability of guideline-informing lipid-lowering clinical trials to contemporary real-world patients with ASCVD. It compared clinical characteristics and long-term outcomes between trial-eligible and ineligible real-world ASCVD patients. Eligibility for lipid-lowering RCTs varies widely across trials and ASCVD subtypes, with earlier trials generally demonstrating higher eligibility rates than more recent ones. Despite differences in clinical characteristics, trial-eligible and ineligible patients exhibit largely comparable long-term risks of recurrent cardiovascular events and all-cause mortality. These findings suggest that guideline-informing lipid-lowering trials are broadly representative of contemporary real-world patients with ASCVD, reinforcing their continued relevance for clinical guidelines. Although some studies suggest an elevated cardiovascular risk with delayed statin initiation, evidence reflecting real-world practice in general health screening settings remains limited. Lee and coworkers3 used nationwide cohort from the National Health Insurance Service (NHIS) database of South Korea, which screened more than four million participants. They showed that delayed initiation of statins after incidentally detected high LDL-C levels was associated with a progressively higher risk of incident myocardial infarction (MI) compared with normolipidemic individuals. The association between delayed initiation of statin and risk of incident MI was more pronounced among younger individuals, males, or those without baseline diabetes. The significantly increasing trend in MI risk with progressively delayed statin initiation remained consistent in stratified and sensitivity analyses. The implementation of guideline-directed medical therapy is limited: in particular, women have been shown to be less likely to receive recommended dose of statins and reach target lipid levels. This has been confirmed in a Dutch study involving 68 150 new users of statin therapy (46% women) with a median age of 65 years. The cumulative incidence of up-titration after 3 years of follow-up was only 12% in men and 10% in women.4 Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies (PCSK9 mAbs) are recommended for high-risk patients if the LDL-C targets are not achieved with statins and ezetimibe. There is limited knowledge on treatment patterns, adherence, and persistence to lipid lowering drugs among patients initiating PCSK9mAbs. Engebretsen and coll. studying the Norwegian Drug Registry observed a 17% treatment gap exceeding 180 days and 28% exceeding 90 days within 3 years among patients initiating PCSK9mAbs. More than 50% stopped statin therapy after initiating PCSK9 mAb whereas 40% discontinued ezetimibe. Atherosclerotic disease, older age and using more than three statin previously were associated with statin and ezetimibe discontinuation.5 Female sex has been historically associated with higher stroke risk in atrial fibrillation (AF), contributing to its inclusion in the CHA2DS2-VASc score. Recent European data suggest the sex-based gap in stroke risk may be narrowing, possibly due to improved risk factor management and greater awareness. The CHA2DS2-VA score is recommended by the latest European AF guidelines; however, evidence on its performance, particularly in anticoagulated patients, remains limited. In a study by Mei et al., in anticoagulated AF patients, female sex was not independently associated with a higher residual risk of stroke/TIA or thromboembolism after adjusting for confounders and the competing risk of death. CHA2DS2-VA and CHA2DS2-VASc scores showed similar predictive ability for residual thromboembolic risk. However, despite having a higher comorbidity burden, women were less likely to receive oral anticoagulation than men, even when clinically indicated.6 Use of non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of gastrointestinal bleeding and is included in prediction tools such as the HAS-BLED and direct oral anticoagulants (DOAC) scores. Previous studies on NSAID-associated bleeding risk in patients with AF receiving DOACs have shown inconsistent results. It remains unclear whether a difference in bleeding risk with different types of DOACs exists and whether the potential bleeding risk is restricted to the gastrointestinal tract or applies to other organ systems. Petersen and coll. have here shown that NSAID use was associated with a nearly two-fold increase in hospital-diagnosed bleeding among patients with AF receiving oral anticoagulation and the increased risk was observed for all types of DOACs, with the highest risk increases were seen for gastrointestinal bleeding.7 Patients with device-detected atrial fibrillation (DDAF) have a lower risk of stroke than patients with electrocardiogram (ECG)-diagnosed AF and the same clinical risk factors. In patients with DDAF, the use of anticoagulation has more ambiguous effects: it slightly reduces the relatively low risk of stroke but also increases the risk of major bleeding. Thus the anticoagulation decisions must balance stroke prevention and increased risk of bleeding in patients with device-detected AF (DDAF). Here, a hypothesis-generating win ratio and win odds analysis integrating death or cardiovascular death, thrombotic events and major bleeds with or without patient-reported outcomes in patients with DDAF and stroke risk factors (median CHA2DS2VA score 3) found no advantage of anticoagulation with edoxaban compared with no anticoagulation. Most patients remained event-free. All-cause death and major bleeding were the most frequent events.8 Previous studies demonstrated the cardioprotective benefits of semaglutide in overweight or obese patients with type 2 diabetes (T2D). However, its therapeutic role in individuals with T2D and normal or low body mass index (BMI <25 kg/m²) has not been clearly established. Here, a study from Kishimori et al.9 have shown that in patients with T2D with a BMI <25 kg/m², semaglutide significantly lowered the 3-year risk of all-cause mortality compared to dipeptidyl peptidase 4 (DPP-4) inhibitors without increasing adverse events. Although semaglutide did not significantly reduce the cumulative incidence of acute MI or stroke, it offered survival benefits and maintained a safety profile similar to that of DPP-4 inhibitors. Heart failure with reduced ejection fraction is a serious condition that affects many people worldwide,10 but recent advances in pharmacological therapy have improved outcomes. This study looked at how well heart failure medications are being used and their impact on survival.11 Out of all patients included, only a small percentage received all the recommended treatments, even though using more medications was linked to better survival. Differences between men and women were also noted, with women being older and having more health problems, but survival rates were similar when comparing men and women of the same age. These results highlight the need for better treatment approaches to improve outcomes for all patients. Several clinical trials showed that the administration of antihypertensive and lipid-lowering drugs in a single pill improves adherence to treatment. Here, a study investigated in a real-world setting the beneficial effect of the perindopril/amlodipine/atorvastatin polypill vs. the corresponding separate-pill combination on treatment adherence.12 Using the healthcare utilization database of Lombardy (Italy), 1110 patients who received the polypill during 2019–2021 were matched with 1110 patients prescribed the same combination in separate tablets. The polypill increased the propensity to be highly adherent to treatment by 3.29 times, irrespective of sex, age, comorbidities. In clinical trials, the use of low-dose aspirin (LDA) (75 or 100 mg) was found to be associated with lower risk of cardiovascular events13 but with an increased incidence of anaemia, independent of major bleeding in healthy older adults. The investigated populations were far different from those observed in routine clinical practice, for which there is currently a lack of analogous studies. Here, a study confirmed a significant association between LDA use and an increased risk of anaemia in older adults in a real-world setting. Anaemia with LDA can occur in 6–10 older individuals out of every 100 LDA users during the first 5 years of treatment. Anaemia in older adults occurred independently of major bleeding.14 Massimo Piepoli (MD PhD FESC FHFA), Andrea Attanasio, Gianluigi Guida, Giandomenico Disabato, and Camilla Mascolo None declared.
No takes yet. Share an insight, caveat, or question.
Attanasio et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: